A Mechanistic In Vivo/Ex Vivo Pharmacokinetic‐Pharmacodynamic Model of Tenofovir for HIV Prevention

• Váldodahkkit: Priya Jayachandran (Dahkki), Maria Garcia-Cremades (Dahkki), Katarina Vučićević (Dahkki), Namandjé N. Bumpus (Dahkki), Peter Anton (Dahkki), Craig Hendrix (Dahkki), Radojka Savić (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2021-03-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Defining tissue and plasma‐specific prophylactic drug concentrations is central to pre‐exposure prophylaxis product development for sexual transmission of HIV‐1. Pharmacokinetic (PK) data from study RMP‐02/MTN‐006 comparing single dose oral tenofovir disoproxil fumarate with single and multiple dose...